Stay updated on Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new site revision label 'Revision: v3.4.2' was added and a general funding/operating status notice previously displayed on the page was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedA government funding lapse notice was added and the page revision updated to v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdditions: glossary toggle, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Deletions: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed, indicating a backend version update with no change to the study data presented.SummaryDifference0.1%

- Check84 days agoChange DetectedLocations now include Ohio as a study site; the Ohio Locations entry was removed and the HHS Vulnerability Disclosure footer link was deleted.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Non-ablative Radiation in NSCLC Clinical Trial page.